Previous 10 | Next 10 |
NuCana (NASDAQ: NCNA ): Q2 GAAP EPS of - £ 0.14 beats by £ 0.05. More news on: NuCana plc, Earnings news and commentary, Healthcare stocks news, Read more ...
Numerous Clinical Data Announcements and Study Initiations Expected in 2019 Current Cash Balance Expected to Fund the Company Into 2021 EDINBURGH, United Kingdom, Aug. 21, 2019 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ: NCNA) announced financial results for the second quarter end...
Gainers : SemiLEDs (NASDAQ: LEDS ) +42% . Waitr Holdings (NASDAQ: WTRH ) +32% . InspireMD (NYSEMKT: NSPR ) +28% . Plus Therapeutics (NASDAQ: PSTV ) +25% . Target (NYSE: TGT ) +19% . XPEL (NASDAQ: XPEL ) +17% . China Green Agriculture (NYSE: CGA ) +16% . Roan Resources (NYSE: ROAN ) ...
Imbalances in Prognostic Factors May Have Impacted Analysis Longer-term Follow-up by Study Sponsor is Ongoing to Determine Path Forward Encouraging Survival Trends Observed in Patient Sub-Groups Receiving Acelarin Monotherapy Informs Future Development in Pancreatic Cancer L...
NUC-7738 is NuCana’s Third ProTide to Enter the Clinic Study Will Enroll Up To 61 Patients with Advanced Solid Tumors EDINBURGH, United Kingdom, July 17, 2019 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ: NCNA), a clinical-stage biopharmaceutical company focused on significantly ...
NuCana Remains on Track to Open Global Phase III Study in 2019 EDINBURGH, United Kingdom, June 12, 2019 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ: NCNA) today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation for the Company’s investigational...
NuCana plc ( NCNA ) has a platform which enables it to take common and ordinarily effective nucleoside chemotherapy drugs like gemcitabine and overcome cellular resistance to them. This vastly increases the efficacy quotient of these drugs. The company's lead drug candidate is Acelarin, which...
EDINBURGH, United Kingdom, May 30, 2019 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ: NCNA) announced today that Hugh Griffith, Chief Executive Officer, and Don Munoz, Chief Financial Officer, will present and host one-on-one meetings at the Jefferies 2019 Healthcare Conference in New York, NY. ...
NuCana (NASDAQ: NCNA ): Q1 GAAP EPS of -£0.17. More news on: NuCana plc, Earnings news and commentary, Healthcare stocks news, Read more ...
Numerous Clinical Data Announcements and Study Initiations Expected in 2019 Current Cash Balance Expected to Fund the Company Into 2021 EDINBURGH, United Kingdom, May 14, 2019 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ: NCNA) announced financial results for the first quarter ended Ma...
News, Short Squeeze, Breakout and More Instantly...
Key Data Readouts on Track for All Programs in 2024 Randomized Phase 2 Study of 182 Second-Line Colorectal Cancer Patients Fully Enrolled NUC-7738 plus Pembrolizumab Demonstrated Encouraging Anti-Cancer Activity in Several Patients who were Resistant to PD-1 Inhibitors ...
Bank of Georgia Group Plc (BDGSF) is expected to report for Q1 2024 iCad Inc. (ICAD) is expected to report for Q1 2024 Yasheng Group (HERB) is expected to report for Q1 2024 Bit Digital Inc. (BTBT) is expected to report $0.01 for Q1 2024 Estrella Immunopharma Inc. (ESLA) is expect...
A look at the top 10 most actives in the United States Jaguar Health Inc. (JAGX) rose 50.1% to $0.1783 on volume of 599,794,977 shares WiSA Technologies Inc. (WISA) rose 248.6% to $6.1 on volume of 197,912,579 shares PROSHARES TRUST (SQQQ) rose 0.0% to $11.44 on volume of 182,001,060 shar...